Ashling Wahner

A series of events took John L. Marshall, MD, down his path of becoming a gastrointestinal oncology leader, with a drive that has also solidified him on the patient journey and enhancing their quality of care.

Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.

The FDA granted fast track designation to NX-5948 for Waldenstrom macroglobulinemia that is relapsed/refractory to at least 2 lines of therapy.

Pembrolizumab plus chemotherapy, followed by olaparib with or without bevacizumab, improved PFS in advanced ovarian cancer.

Blinatumomab plus chemotherapy significantly improved 3-year DFS rates vs chemotherapy alone in pediatric patients with standard-risk pediatric B-ALL.

Andrew Kuykendall, MD, discusses the current role of JAK inhibitors in myelofibrosis and how the use of this class of agents may evolve.

The FDA granted fast track designation to PT217 for the treatment of patients with metastatic de novo or treatment-emergent neuroendocrine prostate cancer.

Sandip P. Patel, MD, discusses the functionality of the IPS test and the potential role of IPS as a biomarker in clinical practice.

Cadonilimab/chemotherapy ± bevacizumab improved survival outcomes vs placebo in frontline persistent, recurrent, or metastatic cervical cancer.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Peter Martin, MD, discusses the current role of BTK inhibitors in MCL and how future research may solidify the use of these agents in this disease.

Abequolixron plus docetaxel generated preliminary efficacy signals in the second- and third-line settings in recurrent advanced nonsquamous NSCLC.

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

The FDA approved the PATHWAY HER2 (4B5) test to identify patients with HER2-positive biliary tract cancer who are eligible for treatment with zanidatamab.

A biologics license application was submitted to the FDA seeking the approval of RP1 plus nivolumab for patients with PD-1 inhibitor–exposed melanoma.

Treatment with afami-cel was associated with long-term persistence in the periphery that led to clinical benefit in patients with synovial sarcoma.

Whitney Goldsberry, MD, discusses patient characteristics and disease factors that sway the decision between available PARP inhibitors in ovarian cancer.

Hope S. Rugo, MD, discusses questions regarding CDK4/6 inhibitors and targeted therapies in HR-positive, HER2-negative advanced breast cancer.

Induction therapy with bendamustine plus obinutuzumab resulted in higher CR rates compared with historical rates of CR with BR in treatment-naive MCL.

The UK MHRA approved frontline toripalimab plus chemotherapy for recurrent/metastatic NPC, as well as for advanced, recurrent, or metastatic ESCC.

The FDA approved the FoundationOne Liquid CDx to identify patients with mNSCLC with MET exon 14 skipping alterations who may be eligible for tepotinib.

The EMA’s CHMP has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.

Mark Awad, MD, PhD, and Jonathan Spicer, MD, PhD, discuss the FDA approval of perioperative nivolumab for patients with resectable NSCLC.

Health Canada has approved momelotinib for the treatment of splenomegaly and/or disease-related symptoms in myelofibrosis with moderate-to-severe anemia.

Kari Wisinski, MD, highlights treatments for HER2– breast cancer, the role of chemotherapy in TNBC, and the benefits of T-DXd for brain metastases.

Early cytokine induction after CAR T-cell therapy infusion predicts CAR expansion in patients with leukemia or lymphoma treated with axi-cel or brexu-cel.

Treatment with magrolimab plus docetaxel led to peripheral CD47 saturation in patients with advanced NSCLC, which correlated with improved outcomes.

Radiomic biomarkers can predict treatment response through assessments of tumor growth in patients with metastatic uveal melanoma treated with roginolisib.

Kari Wisinski, MD, discusses factors that influence her decision between CDK4/6 inhibitors for patients with treatment-naive, HR+ metastatic breast cancer.

Christina S. Baik, MD, MS, discusses the types of HER2 testing that should be performed in NSCLC and the design of the phase 3 Beamion LUNG-2 trial.